News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Quark Pharmaceuticals Inc. Sets IPO of 5 Million Shares at $12-$14 Each
June 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
June 5 (Reuters) - Quark Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, on Tuesday filed with U.S. regulators to sell 5 million shares in an initial public offering at an estimated price of $12 to $14 a share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Mergers & acquisitions
Biopharma Deal Premiums Paint Picture of Cutthroat Negotiations
June 18, 2025
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical
June 17, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
A String of Biopharma Deals Has Piqued Analyst Interest in an M&A Return
June 17, 2025
·
3 min read
·
Annalee Armstrong
